Press Release
Battery Mineral Resources Corp. Announces Agreements with Javelin Global Commodities
–News Direct–
Battery Mineral Resources Corp. (TSXV: BMR) (OTCQB: BTRMF) (Battery or BMR or the Company) is pleased to announce that its Chilean subsidiary, Minera BMR SpA (Minera) has entered into a marketing agreement, master purchase and sale agreement, a copper concentrate pre-payment and advance payment terms arrangements (collectively, the Agreements) with Javelin Global Commodities (Javelin). It is intended that, pursuant to the Agreements, Javelin will market the copper concentrate, gold, silver, and other metals, (Product), produced at the Punitaqui Plant located at the Punitaqui Mining Complex (Punitaqui), provide a US$5,000,000 copper concentrate pre-payment and offer advance payment terms in respect of shipments of Product delivered from time to time in an amount of up to US$20,000,000.
Marketing Agreement
Pursuant to the marketing agreement, Minera appoints Javelin as its exclusive marketing agent for sales of Product to be produced at Punitaqui for a term of 11 years. In consideration for provision of marketing services, Javelin will earn a variable commission based on Product price receivable by Minera from the sale of Product facilitated through Javelins marketing activities. The marketing agreement is subject to pre-agreed upon exclusions for certain Product which will not be marketed by Javelin.
US$5,000,000 Copper Concentrate Prepay
Javelin has agreed, subject to certain terms and conditions, to prepay to Minera US$5,000,000 in respect of future deliveries of copper concentrate made by Minera to Javelin. The prepaid amount is repayable by Minera on or before December 31, 2026, through the delivery of copper concentrate or in cash. The outstanding balance of the prepaid amount will be subject to an advance payment fee chargeable from the date of the advance until the prepaid amount is reduced to zero, at a rate equal to the three-month SOFR (subject to SOFR floor of 2.00%) plus 7.00% per annum. The proceeds of the Prepay are intended to be used to help fund the Punitaqui restart.
In this regard, personnel hiring for the resumption of full operations at Punitaqui remains on schedule. Final mine maintenance at the San Andres mine including rehabilitation of ground support, re-activation of compressed air, ventilation, power, and water in preparation for resumption of full mining operations, commenced in late November with the aim of full operational commissioning of the plant in Q1 and plant start-up in Q2 of 2024.
Payment Terms Arrangement of up to US$20,000,000
Javelin will establish an advance payment terms arrangement (Facility) in an aggregate amount of up to US$20,000,000. The Facility will be used for (a) eligible accounts receivable and inventory on vessel up to the maximum amount of the Facility, (b) eligible shed inventory at the Minera storage yard, subject to a sub-limit of US$2,500,000, and (c) eligible bulk inventory at agreed terminals, subject to a sub-limit of US$5,000,000). An upfront discount of 1% of the maximum Facility amount and an administration discount of US$2,000 per week shall be paid by Minera to Javelin, which may be offset against the price payable by Javelin for the Product shipments. In consideration of Javelin making advance payments, Minera shall pay to Javelin an advance payment discount at a rate equal to three-month SOFR (subject to SOFR floor of 2.00%) plus 7.00% per annum on the principal amount outstanding under the Facility from time to time. BMR and Minera are providing a pledge of certain assets, including over shares in Minera and over rights under certain material agreements of BMR and Minera as conditions of the Facility and the other Agreements.
CEO Commentary
Martin Kostuik, Batterys CEO stated, The consummation of these Agreements with Javelin marks a very critical step in terms of placing the Punitaqui Mine into operational readiness and first concentrate production. We welcome Javelin as a partner and look forward to leveraging their marketing prowess to maximize the value that the sale of copper concentrates will bring to BMR shareholders.
Conditionality and Security
While the Agreements have been entered into, the availability of the copper concentrate prepay and the ability of Minera to borrow under the working capital facility are each subject to the satisfaction of certain terms and conditions.
BMR has agreed to guarantee all obligations and liabilities of Minera under the Agreements. Mineras obligations under the Agreements will be secured by liens in favour of Javelin over assets and material agreements of Minera and BMR.
There are no conversion features into securities of the Company that are associated with the copper concentrate pre-payment or the advance payment terms arrangements, and no bonus securities are to be paid in connection with the Agreements.
About Battery Mineral Resources Corp.
Battery Mineral Resources is a battery minerals company providing shareholders exposure to the global mega-trend of electrification while being focused on growth through cash-flow, exploration, and acquisitions in favourable mining jurisdictions. Battery Minerals mission is the discovery, acquisition, and development of battery metals (namely cobalt, lithium, graphite, and copper), in North America, South America and South Korea and to become a premier and responsible supplier of battery minerals to the electrification marketplace. BMR is currently pursuing a near-term resumption of operations of the Punitaqui Mining Complex, a past copper-gold-silver producer, in the Coquimbo region of Chile. BMR is the largest mineral claim holder in the historic Gowganda Cobalt-Silver Camp in Ontario, Canada, and continues to pursue a focused program to build on the recently announced, +1-million-pound high-grade cobalt resource at McAra. In addition, Battery Mineral owns 100% of ESI Energy Services, Inc. (including ESIs wholly owned USA operating subsidiary, Ozzies, Inc.), a profitable mainline pipeline and renewable energy equipment rental and sales company with operations in Alberta, Canada and Arizona, USA. Battery Mineral Resources is based in Canada and its shares are listed on the TSX Venture Exchange under the symbol BMR and on the OTCQB under the symbol BTRMF. Further information about BMR and its projects can be found on www.bmrcorp.com.
Twitter: @BMRcorp_
Facebook: Battery Mineral Resources Corp. | Facebook
LinkedIn: Battery Mineral Resources Corp.: My Company | LinkedIn
Website: www.bmrcorp.com
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking Statements:
This news release includes certain forward-looking statements under applicable Canadian securities legislation. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections of the Company on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to obtain sufficient financing to complete exploration and development activities, the ability of the Company to secure the Advances under the Loan Agreement, timing of the completion of the Companys audit, risks related to share price and market conditions, the inherent risks involved in the mining, exploration and development of mineral properties, the ability of the Company to meet its anticipated development schedule, government regulation and fluctuating metal prices. Accordingly, readers should not place undue reliance on forward-looking statements. Battery undertakes no obligation to update publicly or otherwise revise any forward-looking statements contained herein, whether as a result of new information or future events or otherwise, except as may be required by law.
Contact Details
Battery Mineral Resources Corp.
Martin Kostuik, CEO
+1 604-229-3830
Corporate Communications
Corporate Communications IBN (InvestorBrandNetwork)
+1 310-299-1717
editor@investorbrandnetwork.com
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/battery-mineral-resources-corp-announces-agreements-with-javelin-global-commodities-757004588
Battery Mineral Resources Corp.
COMTEX_447708180/2655/2024-02-12T16:08:58
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation.
New Zealand, 18th Oct 2024 – In the context of a rapidly aging global population and a growing awareness of health among consumers, the demand for premium oral anti-aging nutritional products is surging. OXYENERGY, a specialized nutritional brand from New Zealand, has developed and produced AGELESS SWITCH, a cutting-edge product based on the concept of “comprehensive anti-aging and stem cell activation,” aiming to create a truly functional anti-aging solution. This innovative approach has quickly garnered widespread attention worldwide, with numerous prominent media outlets covering the product, and endorsements from respected professionals, including professors, nutritionists, and international pageant winners. As a result, AGELESS SWITCH PQQ has gained significant traction, emerging as a dominant new trend in the oral beauty and anti-aging market.
PQQ (Pyrroloquinoline Quinone) holds a highly esteemed position in the fields of biomedical and nutritional sciences, earning the title of “King of Immunity.” Due to its complex extraction process, the purified form of PQQ commands an exceptionally high price on the international market—exceeding the value of gold by over a thousand times. For a long time, this made PQQ available only for research purposes. However, further studies revealed that PQQ can effectively target and neutralize free radicals in the body, mitigating oxidative stress damage to cellular structures. This potent protection of cellular health surpasses that of traditional antioxidants, leading to the widespread adoption of PQQ in anti-aging products.
The AGELESS SWITCH PQQ product builds on traditional PQQ formulations, seeking innovative breakthroughs in both technology and formulation. It focuses on stem cell activation technology and sets a new market benchmark with a high concentration of 50mg per capsule and over 99% purity achieved through patented extraction processes. This product is further enhanced by premium ingredients such as Ergothioneine, Pterostilbene, and Apple Stem Cell Extract. Utilizing advanced 6-in-1 Black Gold Anti-Aging Technology, it upgrades its antioxidant capacity by 60,000 times, establishing the Black Gold Anti-Aging Pyramid and offering a three-step targeted anti-aging solution for full-body rejuvenation.
OXYENERGY’s AGELESS SWITCH PQQ stands out in the industry with its pioneering biotechnology and advanced formulation, positioning itself as a trailblazer driving further development in the anti-aging sector. Its excellent product reputation has sparked a global following, earning it the nickname “the black bandage of oral supplements.” This has ignited an unprecedented AGELESS SWITCH PQQ trend in the global anti-aging market, with countless consumers adopting it in their daily routines to affirm their status as anti-aging enthusiasts. Industry experts have remarked, “The global era of OXYENERGY AGELESS SWITCH has arrived!”
As a global pioneer in the field of dietary nutrition, the New Zealand brand OXYENERGY consistently stays at the forefront of industry development with its forward-thinking vision and scientific expertise. Committed to advancing the anti-aging sector and other health-related fields, OXYENERGY continues to drive breakthroughs and innovations in the global health industry. The brand is leading more consumers toward a younger, healthier future.
Media Contact
Organization: OXYENERGY
Contact Person: sunny chen
Website: https://www.oxyenergy-labs.com/
Email: Send Email
Country: New Zealand
Release Id: 18102418595
The post OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation. appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the “Hong Kong and Macau Medicine and Equipment Connect” policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.
In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.
If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.
Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.
CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the “Hong Kong and Macau Medicine and Equipment Connect” policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.
About ruxolitinib cream
Ruxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].
On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.
Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.
About vitiligo
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5、6].
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.
Reference：
- Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-t…
- Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
- Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura
- Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-7
- Consensus on the diagnosis and treatment of vitiligo (2021 version)
- Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Unleash Your Creative Potential with CreateAI: The Future of AI-Enhanced Content Creation
The digital landscape is evolving at an unprecedented pace, and at the forefront of this transformation is CreateAI—an innovative platform that empowers creators with AI-enhanced tools to unlock their true potential. Whether you’re an aspiring influencer, a meme enthusiast, a business visionary, or a budding game developer, CreateAI offers the resources you need to craft captivating content that inspires and engages. With AI simplifying complex creative processes, the platform enables creators of all levels to effortlessly transform their ideas into reality.
A Platform for Every Creator
At its core, CreateAI is designed to democratize content creation by offering powerful, AI-driven tools that simplify the production of visuals, videos, music, and more. No matter your background or technical expertise, CreateAI equips you with the tools to innovate and produce high-quality content with ease.
The platform’s journey begins with Phase 1: Become an Influencer, where creators can master the art of content creation to engage their audience. With AI-enhanced tools, influencers can elevate their online presence, craft visually appealing posts, and produce captivating content that resonates with their followers. AI’s intuitive capabilities streamline the creative process, allowing you to focus on building authentic connections with your audience.
In Phase 2: Become a Meme Developer, CreateAI introduces an entirely new way to participate in internet culture. Memes have become a dominant form of communication in the digital age, and CreateAI makes meme creation fun and easy. By transforming text into shareable and humorous images, CreateAI’s tools empower users to create viral content effortlessly. Whether you’re aiming to grow your social media presence or simply express creativity, CreateAI brings your ideas to life.
Phase 3: Become a Businessman is for entrepreneurs and business leaders looking to harness the power of AI to elevate their strategies and content. CreateAI enables businesses to develop impactful campaigns, streamline branding efforts, and craft innovative ideas that drive growth. With AI-enhanced tools at your fingertips, you can focus on expanding your business while AI handles the heavy lifting of content creation.
In Phase 4: Become a Game Developer, CreateAI goes beyond content creation to offer an immersive game development experience. The platform’s AI tools allow users to create engaging games with stunning visuals and dynamic elements, all from text-based commands. Whether you’re a seasoned developer or someone new to game design, CreateAI simplifies the complex world of game development, making your vision a reality.
Powerful AI Tools for Every Creative Need
At the heart of CreateAI is a suite of AI-enhanced tools that empower creators to innovate across various mediums:
– /Create Avatar: Transform simple text into lifelike avatars, customized and animated to your specifications. Bring characters to life effortlessly with AI.
– /Create Music: Compose unique music tracks from text, enabling you to create original compositions without needing extensive musical knowledge.
– /Create Image: Generate stunning visuals from text, allowing you to bring your artistic ideas to life with ease.
– /Create Video: Produce engaging, high-quality videos from text-based inputs. Animate and edit seamlessly using AI assistance.
– /Create Meme: Design viral memes effortlessly with AI-driven tools, transforming text into shareable humor that captivates instantly.
– /Create Token Launch: Launch your own cryptocurrency tokens with AI precision, simplifying the process of entering the blockchain world.
– /Create Web: Build visually appealing, functional websites with the help of AI, streamlining the design and development process.
– /Create Game: Develop immersive games by leveraging AI to enhance game design, making the complex process of game development easy and intuitive.
A Strong Ecosystem Backed by Robust Tokenomics
CreateAI’s ecosystem is powered by its native token, $CREATE, which fuels the platform’s operations and growth. With a total supply of 100 million tokens on the Ethereum blockchain, the tokenomics of CreateAI ensures a balanced approach to liquidity, marketing, community incentives, and more. The ecosystem is designed to reward creators and foster a collaborative environment where both the platform and its users thrive.
Join the Future of Creativity
CreateAI is not just a tool—it’s a movement. By joining the CreateAI community, you become part of a vibrant network of creators, developers, and innovators. Whether you’re looking to elevate your content creation, develop new business strategies, or build immersive games, CreateAI provides the tools you need to succeed in today’s rapidly evolving digital landscape.
Start your journey today with CreateAI and transform your creative ideas into reality with AI-enhanced precision. Visit [CreateAI](https://www.createai.io) to learn more and join a new era of creativity.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation.
China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area
Unleash Your Creative Potential with CreateAI: The Future of AI-Enhanced Content Creation
Africa Is The New Site Of Media Confrontation: Daily Post Nigeria Assesses the Situation
Real Street Capital Appoints Gregory Stula as Chairman of the Board
Seaco-online.com Sets Sail with E-Commerce Revamp Poised to Elevate Singapore’s Seafood Shopping Experience
-
Press Release1 week ago
Freedom FX Broker: Celebrating Three Consecutive Years as the Best Forex Broker
-
Press Release1 week ago
Empowering Companies to Cross Capital Market Boundaries: Carat W Holding’s Expertise in Listing and Fundraising in Taiwan, the U.S. and the U.K.
-
Press Release1 week ago
NEXT15 Innovative Advertising Work Platform, Creating a Win-Win Model for Users and Brands
-
Press Release1 week ago
Solana and Ethereum-Based Device Authentication and Authorization Consensus Algorithm Developed by Dono Vault
-
Press Release2 days ago
Indie Fest Carolina to Feature Dancehall/Reggae Sensation Remedy Live in Charlotte
-
Press Release2 days ago
How DLDCUSDT propels the EV industry forward
-
Press Release1 day ago
Growork: The groundbreaking SaaS platform set to revolutionise business connections in the UAE
-
Press Release2 days ago
SafetyXpress Launches Innovative U-Shaped Bollards for Maximum Protection in Commercial and Industrial Spaces